# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Elon Musk has come off as a flagbearer of the mRNA technology, which is seen holding out a lot of promise by scientists.
HC Wainwright & Co. analyst Robert Burns maintains BioNTech (NASDAQ:BNTX) with a Buy and raises the price target from $1...
TD Cowen analyst Yaron Werber maintains BioNTech (NASDAQ:BNTX) with a Hold and raises the price target from $95 to $98.
BMO Capital analyst Etzer Darout maintains BioNTech (NASDAQ:BNTX) with a Outperform and lowers the price target from $123 to...
BioNTech reports Q1 loss, missing revenue expectations. Despite challenges, BioNTech aims for significant growth, fueled by inn...
U.S. stocks are likely to extend their gains as major index futures are modestly higher on Monday. Strong earnings reports cont...
Planned 2024 Financial Year Expenses and Capex R&D expenses: €2.4B-€2.6B SG&A expenses: €700M-€800M Capital expend...